Monashee Investment Management LLC Invests $3.51 Million in Ascentage Pharma Group International - Unsponsored ADR $AAPG

Key Points

• Monashee Investment Management LLC has acquired a new stake in Ascentage Pharma Group International, purchasing 159,942 shares valued at approximately $3.5 million during the first quarter.
• The company operates as a clinical-stage biotechnology firm focused on developing therapies for cancers, hepatitis B virus, and age-related diseases.
• Ascentage Pharma's stock is currently trading around $47.20, with a significant 12-month price range between $16.50 and $47.78.

Monashee Investment Management LLC acquired a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent reporting period.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG traded down $0.52 during mid-day trading on Tuesday, hitting $42.96. The stock had a trading volume of 8,880 shares, compared to its average volume of 40,017. Ascentage Pharma Group International - Unsponsored ADR has a 52-week low of $16.50 and a 52-week high of $48.45. The company has a 50 day simple moving average of $40.40 and a 200 day simple moving average of $28.60. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.